Program european charcot foundation symposium 2012


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Program european charcot foundation symposium 2012

  1. 1. PROGRAMMEEUROPEAN CHARCOT FOUNDATIONSYMPOSIUM 2012Natural History and Gut Microbiota.Forward Players in the Multiple Sclerosis FieldNovember 29, 30 and December 1, 2012Marbella, SpainXVIIIth European Charcot Foundation LectureProf. G. EbersLessons learned from the Natural History studiesAimed at improving Therapeutic Trials MethodologyAnd Designing MS Prevention TrialsThursday November 29, 2012European Charcot FoundationHoeveveld 18a6584 GG Molenhoek (Nijmegen area)The NetherlandsTel.: 31-24-3561954/0031 630 98 59 49Fax : 31-24-3540920www.charcot-ms.euOverview of ProgrammeEuropean Charcot Foundation Lecture Prof. G. EbersChapter ISession 1 Session 1: The risk of MS has changedIntegrated Satellite Symposium GenzymeSession 2 Natural History of Disease EvolutionIntegrated Satellite Symposium NovartisSession 3 Long term prognosis: Lessons for Treatment and Prevention.Chapter IISession 4 Gut immunology and Multiple Sclerosis.Session 5 Gut immunology and Treatment consequences in MSEuropean Charcot Foundation Young Investigators Awards 1
  2. 2. Thursday November 29. 2012 Chair: O.R. Hommes – B. Brochet13.30 XVIII European Charcot Foundation Lecture G. Ebers Lessons learned from the Natural History studies Oxford aimed at improving Therapeutic Trial Methodology and designing MS prevention trials14.30 – 15.00 DiscussionCHAPTER I Natural History of Multiple Sclerosis Chair: G. Ebers – M.D. D’hooghe SESSION 1 The Risk of MS has changed15.00 Understanding the disease Multiple Sclerosis. M. Pugliatti Implications for therapy and prevention Sassari SESSION 2 Natural History of Disease Evolution15.20 Aggressive and Benign Multiple Sclerosis: D. Cottrell Statistical definitions Bristol15.40 Disease Phenotypes Genetics and Epigenetics F. Lublin New York16.00 Clinical Baseline Features and Demographic B. Brochet Aspects of Multiple Sclerosis Bordeaux16.20 – 16.50 Discussion16.50 – 17.20 Coffee break17.30 – 19.00 Integrated Satellite Symposium Genzyme “Time to change the treatment paradigm Chair: for people with MS?” X. Montalban Barcelona White and grey matters A. Traboulsee Vancouver Start safe and smooth F. Lublin New York Hit hard and early G. Giovannoni London Manage disease progression B. Kieseier Düsseldorf General discussion 2
  3. 3. 19.00 Welcome reception Friday November 30, 2012 (morning) SESSION 2 Natural History of Disease Evolution Chair: M. Pugliatti - F. Lublin08.00 Relapses, onset of progression and late A. Scalfari outcomes in Multiple Sclerosis London08.20 Age and accumulation of disability in MS P. Muraro London08.40 Rejuvenation of Regeneration R. Franklin Cambridge09.00 Walking as outcome and therapy in MS M. Daumer Munich09.20 The ideal Epidemiological Study and Pitfalls M.D. D’hooghe Melsbroek09.40 Discussion Invited discussants: S. Pouly P. Muraro10.30 – 11.00 Coffee break11.00 – 12.30 Integrated Satellite Symposium Novartis “Growing experience with once daily Chair: oral Fingolimod” R. Gold Bochum Clinical efficacy and safety of Fingolimod T. Derfuss Basel Oral Fingolimod in clinical practice R. Gold Case based panel discussion: M. Duddy Evolving considerations in MS treatment Newcastle12.30 – 14.00 Lunch Friday November 30, 2012 (afternoon) SESSION 3 Long term prognosis: Lessons for Treatment and Prevention Chair: P. Muraro – D. Cottrell14.00 Introduction G. Ebers Oxford14.20 Prognostic factors influencing long term outcome G. Edan 3
  4. 4. Rennes14.40 A critical analyses of assessment tools for disability S. Cook Newark15.00 MRI. Its status as Surrogate for Long Term clinical Ch. Guttmann Development in Multiple Sclerosis Boston15.30 – 16.00 Coffee breakCHAPTER II Gut immunology and Multiple Sclerosis SESSION 4 Gut immunology and Multiple Sclerosis Chair: H. Wekerle – K. Gurumoorthy16.00 Gut microbiota. From bench to bedside R. Hohlfeld Munich16.20 Systemic human antibody response to gut commensal G. Gorochov Bacteria. How does B-cell hyperactivation occur and Paris what could be its relation to Multiple Sclerosis16.40 Development of the gut associated lymphoid tissue, R. Mebius lessons for early MS Amsterdam17.00 Infection in MS: Friend or foe. On innate immunity K. Mills and autoimmunity Dublin17.20 – 17.50 Discussion20.00 Speakers Dinner Saturday December 1, 2012 SESSION 5 Gut immunology and Treatment consequences in MS Chair: R. Mebius – H. Hohlfeld8.30 Role of the Aryl Hydrocarbon Receptor (AHR) F.J. Quintana in the control of CNS autoimmunity by the Boston microenvironment8.50 T-cell lineage differentiation J. Walter Lincoln9.10 Microbiota and spontaneous CNS Autoimmunity: K. Gurumoorthy Lessons for Multiple Sclerosis Munich9.30 – 10.00 Coffee break10.00 Bowel and brain. New clinical trials in Multiple L.H. Kasper Sclerosis Lebanon NH10.20 – 11.00 Discussion and summary H. Wekerle 4
  5. 5. Munich11.00 Young Investigators Awards11.30 Closure O.R. Hommes Molenhoek12.30- 13.00 Lunch 5